Showing results (201-210 of 530) with videos related to

Sort By:
Pageof 53
Urology|December 29, 2020
Social and Clinical Correlates of Neoadjuvant Chemotherapy in Medicare Beneficiaries With Muscle Invasive Bladder Cancer From 2004-2015Yaw A Nyame, Sarah K Holt, Leonidas N Diamontopoulos, et al.
Oncotarget|October 21, 2016
Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostateMichael T Schweizer, Heather H Cheng, Maria S Tretiakova, et al.
Cell Systems|May 21, 2018
Interrogation of Mammalian Protein Complex Structure, Function, and Membership Using Genome-Scale Fitness ScreensJoshua Pan, Robin M Meyers, Brittany C Michel, et al.
Urology|January 14, 2014
Challenges and recommendations for early identification of metastatic disease in prostate cancerE David Crawford, Nelson N Stone, Evan Y Yu, et al.
Molecular Cancer Therapeutics|August 12, 2018
iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic CancerJustin H Lo, Liangliang Hao, Mandar D Muzumdar, et al.
Investigative Ophthalmology & Visual Science|September 15, 2012
High throughput mass spectrometry-based mutation profiling of primary uveal melanomaAnthony B Daniels, Joo-Eun Lee, Laura E MacConaill, et al.
Nature Cell Biology|August 4, 2014
Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin SLisa Sevenich, Robert L Bowman, Steven D Mason, et al.
European Urology|February 16, 2022
Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical TrialBradley McGregor, Peter H O'Donnell, Arjun Balar, et al.
Cancer Causes & Control : CCC|January 17, 2026
Perspectives on GUIDE (Guiding participation toward understanding, inclusion, diversity, and equity for cancer trials): a clinical trial access interventionKristine A Karvonen, Jean A McDougall, Sarah D Hohl, et al.
European Journal of Cancer (Oxford, England : 1990)|May 16, 2017
Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancerAndrew J Armstrong, Susan Halabi, Patrick Healy, et al.
Pageof 53